Medicare’s lack of negotiating power is largely blamed for the sky-high drug prices that many Americans can’t afford. That could soon change, however, if Democrats’ new proposal for decreased drug pricing passes as part of President Biden’s Build Back Better Act. Read More
Related Articles
Fidelity, Nasdaq, and AngelList all agree on one thing: Cap tables need some work
Posted on Author admin
A group of 37 firms and companies are trying to homogenize a rather non-homogenous document. Read More
A U. S. afternoon selloff spoils a global market rebound
Posted on Author admin
It looked set to be a resurgent Monday for the global markets until U. S. stocks swooned to end the day. Read More
U.S. futures climb as investors focus on bank and tech stocks—crypto wobbles
Posted on Author admin
U.S. futures are gaining on Thursday, led by tech. Read More